HC Wainwright Lifts Earnings Estimates for Maze Therapeutics

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Stock analysts at HC Wainwright raised their Q3 2025 EPS estimates for shares of Maze Therapeutics in a report issued on Wednesday, August 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will earn ($0.71) per share for the quarter, up from their previous estimate of ($1.06). HC Wainwright currently has a “Buy” rating and a $34.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($2.73) EPS, FY2027 earnings at ($2.97) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($1.16) EPS.

A number of other research firms also recently issued reports on MAZE. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Wedbush started coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They set an “outperform” rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.60.

Maze Therapeutics Price Performance

MAZE stock opened at $13.50 on Friday. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $19.19. The business has a 50 day moving average of $13.93.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alphabet Inc. acquired a new position in Maze Therapeutics in the 1st quarter valued at $26,561,000. Bank of New York Mellon Corp acquired a new position in Maze Therapeutics in the 1st quarter valued at $190,000. General Catalyst Group Management LLC acquired a new position in Maze Therapeutics in the 1st quarter valued at $11,405,000. Bessemer Group Inc. acquired a new position in Maze Therapeutics in the 1st quarter valued at $5,305,000. Finally, TRV GP V LLC acquired a new position in Maze Therapeutics in the 1st quarter valued at $10,468,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.